Patents by Inventor Daniel Sitar

Daniel Sitar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for assaying the activity of spermidine/spermine N1-acetyltransferase
    Patent number: 11999990
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: June 4, 2024
    Assignee: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • METHOD OF DETECTING LUNG CANCER
    Publication number: 20230251261
    Abstract: A biomarker panel and method for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 10, 2023
    Inventors: Rashid Bux, Daniel Sitar
  • Method of detecting lung cancer
    Patent number: 11656229
    Abstract: A biomarker panel for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof. A biomarker panel for a serum test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of valine, arginine, ornithine, methionine, spermidine, spermine, diacetylspermine, C10:2, PC aa C32:2, PC ae C36:0, and PC ae C44:5; and lysoPC a C18:2, or a combination thereof.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: May 23, 2023
    Assignee: BioMark Cancer Systems Inc.
    Inventors: Rashid Bux, Daniel Sitar
  • METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE
    Publication number: 20230069827
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: August 25, 2022
    Publication date: March 9, 2023
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Method for assaying the activity of spermidine/spermine N-acetyltransferase
    Patent number: 11441168
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: September 13, 2022
    Assignee: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Method For Assaying The Activity Of Spermidine/Spermine N1-Acetyltransferase
    Publication number: 20220033875
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: August 19, 2021
    Publication date: February 3, 2022
    Applicant: BioMark Technologies Inc.
    Inventors: Brian CHENG, Rashid BUX, Daniel SITAR
  • METHOD OF DETECTING LUNG CANCER
    Publication number: 20180180618
    Abstract: A biomarker panel for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof. A biomarker panel for a serum test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of valine, arginine, ornithine, methionine, spermidine, spermine, diacetylspermine, C10:2, PC aa C32:2, PC ae C36:0, and PC ae C44:5; and lysoPC a C18:2, or a combination thereof.
    Type: Application
    Filed: June 27, 2016
    Publication date: June 28, 2018
    Applicant: BioMark Cancer Systems Inc.
    Inventors: Rashid Bux, Daniel Sitar
  • Method For Assaying The Activity Of Spermidine/Spermine N1-Acetyltransferase
    Publication number: 20140315217
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Applicant: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Monoclonal Antibody For Acetylamantadine
    Publication number: 20140287446
    Abstract: A method of producing an antibody comprises immunizing a mammal with an amine-derivative of acetylamantadine, immunizing the mammal with acetylamantadine, and producing the antibody from the mammal. The antibody recognizes acetylamantadine but does not recognize amantadine.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 25, 2014
    Applicant: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Gregorio Aversa, Bram Ramjiawan, Daniel Sitar